Skin Cancer News

Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma

Pembrolizumab With Dabrafenib and Trametinib Shows Efficacy, But High TRAEs, in Melanoma

Pembrolizumab plus dabrafenib and trametinib showed a nonsignificant improvement in PFS, but also higher rates of grade 3 to grade 5 TRAEs in advanced melanoma.

First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma

First-Line Nivolumab Alone or With Ipilimumab Continues to Show Durable Survival Benefits in Advanced Melanoma

First-line nivolumab with or without ipilimumab continues to show durable survival benefits in advanced, unresectable melanoma.

Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma

Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma

T-VEC elicited substantially higher ORR in a real-world population compared with the rate that was seen in the drug maker's phase 3 trial.

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.

The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear

The Optimal Neoadjuvant Regimen of Checkpoint Inhibitors in High-Risk Melanoma Is Unclear

Treatment with ipilimumab plus nivolumab in the neoadjuvant setting resulted in high patient response rates — but it was linked to high toxicity, as well.

Neoadjuvant Combination Checkpoint Inhibition May Be Feasible for Stage III Melanoma

Neoadjuvant Combination Checkpoint Inhibition May Be Feasible for Stage III Melanoma

Future studies on checkpoint inhibition in melanoma must evaluate ways of reducing toxicity.

Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response

Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response

Existing studies that summarize the risks of breast implants are not adequately powered to detect all harms, alleged authors of a study including nearly 100,000 patient outcomes.

Predictors of Response to Checkpoint Inhibitors in Melanoma Revealed

Predictors of Response to Checkpoint Inhibitors in Melanoma Revealed

A computational tool appears to accurately tease out the portion of patients who might respond to checkpoint inhibitors from those who are likely to be resistant.

Limited Local Lymph Node Excision Plus Radiotherapy May Be Effective in Melanoma

Limited Local Lymph Node Excision Plus Radiotherapy May Be Effective in Melanoma

Previous studies have evaluated the effects of limited local node excision plus radiotherapy among patients with melanoma in this subgroup, but had conflicting results.

Adjuvant Bevacizumab May Not Improve Overall Survival in Resected Melanoma

Adjuvant Bevacizumab May Not Improve Overall Survival in Resected Melanoma

Previous studies have demonstrated that the vascular endothelial growth factor inhibitor bevacizumab is active in melanoma, and may be effective in the maintenance setting.

Frequency of Tanning, Risk for Melanoma Higher in Gym Tanners

Frequency of Tanning, Risk for Melanoma Higher in Gym Tanners

The use of tanning beds and/or booths and their availability in gyms may increase the frequency of indoor tanning for physically active adults, a combination that further exacerbates their risk for melanoma.

Do Sunless Tanners Have Fewer Skin Cancer Risk Behaviors?

Do Sunless Tanners Have Fewer Skin Cancer Risk Behaviors?

People who elect to undergo sunless tanning tend to continue behaviors that could increase their risk of skin cancer.

Skin Cancer Education May Improve Sun Protection Practices Among Organ Transplant Recipients

Skin Cancer Education May Improve Sun Protection Practices Among Organ Transplant Recipients

The use of multiple sun protection measures was defined as the use of 2 or more of these measures more than 50% of the time when the individual was outdoors.

Reprogramming T Cells Without Using Viral Vectors

Reprogramming T Cells Without Using Viral Vectors

According to recent research, scientists may not need to rely on the use of viral vectors to edit the genes of primary immune cells when creating cell and gene therapies.

FDA Approves Encorafenib Plus Binimetinib for BRAF V600E, V600K Mutation-Positive Melanoma

FDA Approves Encorafenib Plus Binimetinib for BRAF V600E, V600K Mutation-Positive Melanoma

The FDA based their approval on findings from the phase 3 COLUMBUS study, in which researchers randomly assigned patients with BRAF V600-mutant melanoma to receive encorafenib plus binimetinib, encorafenib, or vemurafenib.

Radiation and Immunotherapy Show Possible Survival Advantage in Melanoma-Related Brain Metastases

Radiation and Immunotherapy Show Possible Survival Advantage in Melanoma-Related Brain Metastases

Results from a small study show that PD-1 inhibitors could work synergistically with radiosurgery to promote slightly longer survival times.

FDA Accepts sBLA for Pembrolizumab as Adjuvant Therapy for Melanoma

FDA Accepts sBLA for Pembrolizumab as Adjuvant Therapy for Melanoma

If approved, the new indication could mean pembrolizumab could be used for patients with melanoma.

Complete Lymph Node Dissection May Not Improve Outcomes in Melanoma

Complete Lymph Node Dissection May Not Improve Outcomes in Melanoma

When compared with watchful waiting, CLND did not improve survival outcomes among patients with malignant melanoma who have positive SLNB.

Long-Term Data Show Nivolumab May Provide Sustained Benefit Compared With Ipilimumab

Long-Term Data Show Nivolumab May Provide Sustained Benefit Compared With Ipilimumab

Preliminary findings from CheckMate 238 show treatment with nivolumab significantly prolonged recurrence-free survival compared with ipilimumab in patients with resected stage III/IV melanoma after a minimum 18-month follow-up.

Latest AJCC Edition Staging System May Not Be As Effective in Differentiating Survival in Melanoma

Latest AJCC Edition Staging System May Not Be As Effective in Differentiating Survival in Melanoma

Study authors conducted a study comparing the prognostic and discriminatory ability for survival with the 7th and 8th Editions.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs